The run-in phase of the prospective WSG-ADAPT HR+/HER2-trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Nitz, Ulrike; Gluz, Oleg; Kreipe, Hans H.; Christgen, Matthias; Kuemmel, Sherko; Baehner, Frederick L.; Shak, Steven; Aktas, Bahriye; Braun, Michael; Ludtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Nuding, Benno; Darsow, Maren; Schumacher, Claudia; Krauss, Katja; Malter, Wolfram; Thill, Marc; Warm, Mathias; Wuerstlein, Rachel; Kates, Ronald E.; Harbeck, Nadia

The run-in phase of the prospective WSG-ADAPT HR+/HER2-trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Autor(en):

Nitz, Ulrike; Gluz, Oleg; Kreipe, Hans H.; Christgen, Matthias; Kuemmel, Sherko; Baehner, Frederick L.; Shak, Steven; Aktas, Bahriye; Braun, Michael; Ludtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Nuding, Benno; Darsow, Maren; Schumacher, Claudia; Krauss, Katja; Malter, Wolfram; Thill, Marc; Warm, Mathias; Wuerstlein, Rachel; Kates, Ronald E.; Harbeck, Nadia

Tübinger Autor(en):

Grischke, Eva-Maria

Erschienen in:

Therapeutic Advances in Medical Oncology (2020), Bd. 12, Article 1758835920973130

Verlagsangabe:

Sage Publications Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1177/1758835920973130

ISSN:

1758-8359